Trial Profile
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2021
Price :
$35
*
At a glance
- Drugs PTR 01 (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions; First in man
- Sponsors Phoenix Tissue Repair
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 10 Jul 2020 According to a Phoenix Tissue Repair media release, interim data from this trial will be presented at Society for Pediatric Dermatologys (SPD) 45th Annual Meeting, to be held virtually July 10 to 12, 2020.
- 30 Jun 2020 Planned primary completion date changed from 31 Jul 2020 to 30 Nov 2020.